XML 57 R45.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaborative Arrangements - Schedule of Collaborative Arrangement Transactions (Details) - Collaborative Arrangement - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
AstraZeneca    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Receivables from counterparty $ 31  
Payables to counterparty 783  
AstraZeneca | Revenue    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Total Sales 33  
AstraZeneca | Materials and production    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Expenses 12  
AstraZeneca | Marketing and administrative    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Expenses 7  
AstraZeneca | Research and development    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Expenses 29  
Bayer AG    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Receivables from counterparty 35  
Payables to counterparty 0  
Bayer AG | Revenue    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Product sales, net 43 $ 31
Profit sharing 25 53
Total Sales 68 84
Bayer AG | Materials and production    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Expenses 27 23
Bayer AG | Marketing and administrative    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Expenses 8 7
Bayer AG | Research and development    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Expenses $ 32 $ 22